Evidence map›Paper›PMID 22820286›Full record

ArticleThe Journal of clinical investigation2012

How many neutrophils are enough (redux, redux)?

Samuel C Silverstein, Raul Rabadan

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Towards modeling phage therapy.PLoS computational biology · 2026
    Article
  2. Mathematical Modeling ofFrontiers in physiology · 2017
    Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Samuel C Silverstein
Raul Rabadan
Columbia University · US

Funding

Nation Center: Multi-Scale Study- Cellular Networks(RMI)U54CA121852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2005 to 2015
$37.4M
ROLE OF MONONUCLEAR LEUKOCYTES IN IMMUNITYR01AI020516 · NIAID · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SILVERSTEIN, SAMUEL CHARLES · 1985 to 2009
$2.0M
MONONUCLEAR LEUKOCYTES AND IMMUNITYR37AI020516 · NIAID · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SILVERSTEIN, SAMUEL CHARLES · 1994 to 2003
$1.4M
Integrated discovery and hypothesis testing of new associations in rare diseasesR01LM010140 · NLM · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2009 to 2010
$1.1M
NCI NIH HHS U54 CA121852NCI NIH HHS U54 CA121852-05NIAID NIH HHS AI-20516-026NLM NIH HHS 1R01LM010140-01NLM NIH HHS R01 LM010140
6 · The paper itself

Abstract

Many chemotherapeutic regimens produce neutropenia, which predisposes to microbial infection. However, not all neutropenic individuals develop infections, so the ability to predict this outcome would be a powerful clinical tool. In this issue of the JCI, Malka et al. describe a dynamic system model of neutrophil bactericidal activity that confirms and extends the concept of critical neutrophil concentration. The authors demonstrate that when the neutrophil concentration approaches the critical concentration, bacterial populations in contact with them exhibit bistability. Their experimental findings raise the intriguing possibility of greater variability in bactericidal activity of neutrophils from healthy adults than heretofore recognized; their model predicts that this could have life-and-death consequences.

Identifiers

PMID22820286
PMCPMC3533502
OpenAlexW2037962031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.